2-(4-amino-3-methylphenyl)-6-fluorobenzothiazole | 328087-13-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 2-(4-amino-3-methylphenyl)-6-fluorobenzothiazole
• 英文别名: 4-(6-fluorobenzo[d]thiazol-2-yl)-2-methylaniline；6F 203；6-fluoro-2-(4'-amino-3'-methylphenyl)benzothiazole；[4-(6-Fluoro-1,3-benzothiazol-2-yl)-2-methylphenyl]amine；4-(6-fluoro-1,3-benzothiazol-2-yl)-2-methylaniline
• CAS: 328087-13-4
• 化学式: C₁₄H₁₁FN₂S
• 分子量: 258.319
• InChiKey: WKAIATUUHWQMHK-UHFFFAOYSA-N

物化性质

• 熔点：
  203-205 °C
• 沸点：
  440.1±55.0 °C(Predicted)
• 密度：
  1.329±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-amino-3-methylphenyl)-6-fluorobenzothiazole 在 盐酸 、 WSC*HCl 、 1-羟基苯并三唑 作用下， 以 二氯甲烷 为溶剂， 反应 50.0h， 生成 (S)-2,6-diaminohexanoic acid [4-(6-fluoro-benzothiazol-2-yl)-2-methylphenyl]amide dihydrochloride
  参考文献：
  名称：

  Antitumor Benzothiazoles. 16. Synthesis and Pharmaceutical Properties of Antitumor 2-(4-Aminophenyl)benzothiazole Amino Acid Prodrugs

  摘要：

  A series of water-soluble L-lysyl- and L-alanyl-amide prodrugs of the lipophilic antitumor 2-(4-aminophenyl)benzothiazoles has been synthesized to address formulation and bioavailability issues related to the desired parenteral administration of the chosen clinical candidate. The prodrugs exhibit the required pharmaceutical properties of good water solubility (in weak acid) and stability at ambient temperature and degradation to free base in vivo. The lysyl-amide of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (NSC 710305, 6d) has been selected for phase 1 clinical evaluation.

  DOI：

  10.1021/jm011025r
• 作为产物：
  描述：

  3-甲基-4-硝基苯甲酰氯 在 劳森试剂 、 吡啶 、 tin(II) chloride dihdyrate 、 sodium hydroxide 、 potassium hexacyanoferrate(III) 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 17.0h， 生成 2-(4-amino-3-methylphenyl)-6-fluorobenzothiazole
  参考文献：
  名称：

  康维他汀-苯并噻唑杂化物作为微管蛋白聚合抑制剂和细胞凋亡诱导剂的顺式限制性三唑/四唑模拟物的合成及生物学评价

  摘要：

  通过修饰康维他汀药效团合成了一系列秋水仙碱位点结合微管蛋白抑制剂。环B被药理学上相关的苯并噻唑支架取代，烯键的顺式构型受到三唑和四唑环的结合的限制，这可以通过与微管蛋白抑制剂（如康培他汀（CA-4））的结构相似来实现。评估了这些化合物对所选癌细胞系的抗增殖活性，并开发了对结构活性关系的见解。最有效的化合物（9a和9b）具有与CA-4相当的抗增殖作用。G2 / M期的有丝分裂细胞周期停滞揭示了微管动力学的破坏，这已在细胞水平上通过微管蛋白聚合测定法和免疫细胞化学研究得到证实。蛋白质印迹分析表明，这些化合物在可溶性级分中积累了更多的微管蛋白。秋水仙碱竞争性结合试验和分子对接研究表明，这些模拟物在微管蛋白的秋水仙碱位点的结合与CA-4相似。此外，通过Hoechst染色，膜联蛋白-V-FITC分析，线粒体膜电位，ROS生成和caspase-3活化来研究其对有丝分裂阻滞后凋亡细胞死亡的触发作用。

  DOI：

  10.1016/j.bmc.2016.12.010

文献信息

• [EN] METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS<br/>[FR] PROCÉDÉS DE CULTURE ET/OU D'EXPANSION DE CELLULES SOUCHES ET/OU DE CELLULES PROGÉNITRICES DÉTERMINÉES D'UNE LIGNÉE À L'AIDE DE COMPOSÉS AMIDO
  申请人：IDEAYA BIOSCIENCES INC

  公开号：WO2020018848A1

  公开（公告）日：2020-01-23

  Provided are methods for expanding stem cells and/or lineage committed progenitor cells, such as hematopoietic stems cells and/or lineage committed progenitor cells, at least in part, by using compounds that antagonize AhR. The compounds are represented by formulae (I) (II) (III) (IV), wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification. Also provided are compositions comprising stem cells and/or lineage committed progenitor cells expanded by methods disclosed herein and methods for the treatment of diseases treatable by same.

  提供了一种扩增干细胞和/或系谱承诺的前体细胞的方法，例如造血干细胞和/或系谱承诺的前体细胞，至少部分地通过使用拮抗AhR的化合物。这些化合物由公式 (I) (II) (III) (IV) 表示，其中字母和符号 a、b、c、d、e、f、g、Z、R1b、R2a 和 R2b 在说明书中有提供的含义。还提供了包含通过本文披露的方法扩增的干细胞和/或系谱承诺的前体细胞的组合物，以及用于治疗可通过相同方法治疗的疾病的方法。
• [EN] AMIDO COMPOUNDS AS AhR MODULATORS<br/>[FR] COMPOSÉ AMIDO UTILISÉS COMME MODULATEURS DU AHR
  申请人：IDEAYA BIOSCIENCES INC

  公开号：WO2019018562A1

  公开（公告）日：2019-01-24

  Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.

  本文提供了化合物、组合物及使用这些化合物和组合物治疗至少部分受AhR调节的疾病的方法。这些化合物由以下公式表示：公式（I）、（II）、（III）、（iv）：其中字母和符号a、b、c、d、e、f、g、Z、R1b、R2a和R2b的含义如规范中所述。
• Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
  作者：Christopher J. Smedley、Qinheng Zheng、Bing Gao、Suhua Li、Andrew Molino、Hendrika M. Duivenvoorden、Belinda S. Parker、David J. D. Wilson、K. Barry Sharpless、John E. Moses

  DOI：10.1002/anie.201813761

  日期：2019.3.26

  report here the first SuFEx‐based procedure for the efficient synthesis of pharmaceutically important triflones and bis(trifluoromethyl)sulfur oxyimines from sulfonyl fluorides and iminosulfur oxydifluorides, respectively. The new process involves rapid S−F exchange with trifluoromethyltrimethylsilane (TMSCF3) upon activation by potassium bifluoride in anhydrous DMSO. The reaction tolerates a wide

  SuFEx是新一代点击化学转化，利用了S-F键的独特特性及其与亲核试剂进行近乎完美的反应的能力。我们在这里报告了第一个基于SuFEx的程序，可分别从磺酰氟和亚氨基硫代二氟化物有效合成药学上重要的三氟甲酮和双（三氟甲基）硫代亚氧肟酮。新工艺涉及与三氟甲基三甲基硅烷（TMSCF 3）的快速S-F交换）在无水DMSO中被氟化氢激活。该反应可耐受多种底物，并且可在温和条件下进行而无需色谱纯化。提出了一种试探性机制，涉及三氟甲基阴离子通过五配位中间体对S-F进行亲核取代。通过双（三氟甲基）硫氧亚胺的合成和选择性抗癌性能证明了后期SuFEx三氟甲基化的效用。
• [EN] SUBSTITUTED 2-ARYLBENZAZOLE COMPOUNDS AND THEIR USE AS ANTITUMOUR AGENTS<br/>[FR] COMPOSES DE 2-ARYLBENZAZOLE SUBSTITUES ET LEUR UTILISATION COMME AGENTS ANTITUMORAUX
  申请人：CANCER RES CAMPAIGN TECH

  公开号：WO2001014354A1

  公开（公告）日：2001-03-01

  Substituted 2-phenylbenzazole compounds of formula (I) wherein X represents S or O and Q represents a direct bond, -CH2- or -CH=CH-, exhibit selective antiproliferative activity in respect of mammalian tumour cells. At least in preferred embodiments the benzene ring of the benzazole nucleus has a halogen substituent, preferably fluorine, and the 2-phenyl group has a 4'-amino substituent which may be conjugated with an amino acid to provide a water soluble amino acid amide prodrug or salt thereof.

  公式（I）中的2-苯基苯并咪唑化合物，其中X代表S或O，Q代表直接键，-CH2-或-CH=CH-，在哺乳动物肿瘤细胞中表现出选择性抗增殖活性。在至少优选实施例中，苯并咪唑核的苯环具有卤素取代基，优选为氟，而2-苯基基团具有4'-氨基取代基，可以与氨基酸结合以提供水溶性氨基酸酰胺前药或其盐。
• Antitumor Benzothiazoles. 14. Synthesis and in Vitro Biological Properties of Fluorinated 2-(4-Aminophenyl)benzothiazoles
  作者：Ian Hutchinson、Mei-Sze Chua、Helen L. Browne、Valentina Trapani、Tracey D. Bradshaw、Andrew D. Westwell、Malcolm F. G. Stevens

  DOI：10.1021/jm001104n

  日期：2001.4.1

  Synthetic routes to a series of mono- and difluorinated 2-(4-amino-3-substituted-phenyl)benzothiazoles have been devised. Whereas mixtures of regioisomeric 5- and 7-fluorobenzothiazoles were formed from the established Jacobsen cyclization of precursor 3-fluorothiobenzanilides, two modifications to this general process have allowed the synthesis of pure samples of these target compounds. Fluorinated 2-(4-aminophenyl)benzothiazoles were potently cytotoxic (GI(50) < 1 nM) in vitro in sensitive human breast MCF-7 (ER+) and MDA 468 (ER-) cell lines but inactive (GI(50) > 10 muM) against PC 3 prostate, nonmalignant HBL 100 breast, and HCT 116 colon cells. The biphasic dose-response relationship characteristically shown by the benzothiazole series against sensitive cell lines was exhibited by the 4- and 6-fluorobenzothiazoles (10b,d) but not by the 5- and 7-fluoro-benzothiazoles (10h,i). The most potent broad spectrum agent in the NCI cell panel was 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (10h) which, unlike the g-fluoro isomer (10d), produces no exportable metabolites in the presence of sensitive MCF-7 cells. Induction of cytochrome P450 CYP1A1, a crucial event in determining the antitumor specificity of this series of benzothiazoles, was not compromised. 10h is currently the focus of pharmaceutical and preclinical development.